Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioCryst Pharmaceuticals, Inc. (BCRX) had Revenue of $145.53M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$145.53M
Net Income	$0.03M
Cost of Goods Sold	$4.57M
Gross Profit	$140.97M
Operating Expenses	$124.31M
Operating Income	$21.23M
Non-Operating Income/Expense	$-20.47M
Pre-Tax Income	$0.76M
Normalized Pre-Tax Income	$0.76M
Income after Taxes	$0.03M
Income from Continuous Operations	$0.03M
Consolidated Net Income/Loss	$0.03M
Normalized Income after Taxes	$0.03M
EBIT	$21.23M
EBITDA	$20.18M
Weighted-Average Shares Outstanding (Basic)	208.88M
Weighted-Average Shares Outstanding (Diluted)	215.26M
Earnings per Share (EPS) (Basic)	$0.00
Earnings per Share (EPS) (Diluted)	$0.00
Balance Sheet Financials
Current Assets	$409.98M
Property, Plant, and Equipment	$7.59M
Long-Term Assets	$70.07M
Total Assets	$480.05M
Current Liabilities	$139.85M
Long-Term Debt	$784.34M
Long-Term Liabilities	$792.12M
Total Liabilities	$931.97M
Common Equity	$-451.93M
Tangible Shareholders Equity	$-451.93M
Shareholders Equity	$-451.93M
Common Shares Outstanding	209.21M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-27.52M
Cash Flow from Investing Activities	$27.09M
Cash Flow from Financial Activities	$0.53M
Beginning Cash	$106.32M
End Cash	$106.88M
Increase/Decrease in Cash	$0.56M
Stock-Based Compensation	$21.37M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.93
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.36
Debt to Equity Ratio	-1.82
Gross Margin	96.86%
Operating Margin	14.59%
EBIT Margin	14.59%
EBITDA Margin	--
Pre-Tax Profit Margin	0.52%
Profit Margin	0.02%
Free Cash Flow	$-27.66M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.30
Inventory Turnover	0.66
Receiveable Turnover	1.56
Days Sales in Receivables	57.76
Return on Equity	-0.01%
Return on Tangible Equity	-0.01%
Return on Assets	0.01%
Return on Investments	0.01%
Book Value Per Share	$-2.16
Free Cash Flow per Share	$-0.13
Operating Cash Flow per Share	$-0.13

Data from Zacks Investment Research, Inc.